Clinical Report: The JinHuangJieDu Formula Reduces SARS-CoV-2 Infection
Overview
The JinHuangJieDu (JHJD) formula demonstrates significant efficacy in inhibiting SARS-CoV-2 infection by disrupting the RBD-ACE2 interaction and modulating inflammation. This study highlights its potential as a therapeutic candidate against COVID-19, particularly against the Omicron variant.
Background
The COVID-19 pandemic has led to millions of infections and deaths globally, necessitating the development of effective treatments. Traditional Chinese Medicine (TCM) has been utilized in China for COVID-19 management, showing promise in symptom alleviation and recovery. Understanding the mechanisms of TCM formulations like JHJD is crucial for integrating them into contemporary treatment strategies.
Data Highlights
Effect
Outcome
RBD-ACE2 Binding Inhibition
Effective against wildtype and Omicron
Pseudovirus Infection Inhibition
Significant reduction observed
Identified Ingredients
375 active ingredients
Target Genes
338 targets identified
Significant Pathways
63 pathways related to infection/inflammation
Key Findings
JHJD effectively blocks RBD binding to ACE2, inhibiting viral entry.
Demonstrated superior efficacy against Omicron sub-variants.
Network pharmacology identified 375 ingredients and 338 target genes.
CCND1 and HIF1A were validated as pivotal genes in inflammation modulation.
JHJD targets HIF-1α to alleviate virus-induced inflammation.
Clinical Implications
The JHJD formula presents a dual mechanism of action that could enhance COVID-19 treatment strategies. Its ability to inhibit viral entry and reduce inflammation may provide a complementary approach alongside conventional therapies.
Conclusion
JHJD represents a promising therapeutic candidate for COVID-19, particularly in light of emerging variants. Further clinical evaluation is warranted to establish its efficacy and safety in broader patient populations.
